When a Georgia Medicaid prescription gets denied, the decision usually runs through a Pharmacy Benefit Manager (PBM) or the health plan that hired one. Federal law puts limits on that process that most families never hear about: a state may require prior authorization only if its approval system responds within 24 hours and provides for at least a 72-hour supply in an emergency situation, and every denial, fee-for-service or managed care, comes with appeal rights.

In This Guide

Who runs your Georgia Medicaid drug benefit (the PBM)

Most Georgia Medicaid members never deal with a Pharmacy Benefit Manager directly, but a PBM often sits behind the coverage decision on a prescription. A PBM is a third-party administrator that typically processes pharmacy claims at the point of sale, builds the pharmacy network, manages the drug formulary, runs prior authorization and step therapy, and negotiates rebates with drug makers. It is not a pharmacy, and it is not your health plan.

Which PBM handles your prescriptions depends on how you are enrolled.

One Georgia-specific point removes a common source of confusion: the drug list is not the same everywhere. A state study of Georgia Medicaid found four entities providing coverage, the three CMOs plus the fee-for-service program, "resulting in four different drug lists," and noted that CMOs or their subcontracted PBMs generally prefer to manage their own drug lists. DCH's own managed care page links a separate drug formulary for each CMO. So a drug preferred under one CMO can require prior authorization under another, and the fee-for-service drug list does not govern a CMO member. That four-list description is drawn largely from a January 2023 state study, so confirm the formulary that applies to you with DCH or your CMO.

Why a Georgia Medicaid prescription gets denied

A pharmacy rejection on a Georgia Medicaid drug usually comes down to one of a few PBM rules:

  • Prior authorization (PA) required. The drug is not on the preferred list, or it carries a clinical restriction. Your prescriber must submit documentation and get approval first.
  • Step therapy. You must try a preferred drug in the same class first. If it does not work or you cannot tolerate it, your prescriber can request the non-preferred drug with that history documented.
  • Quantity limit. The plan caps how much can be dispensed per fill or per period. A higher quantity can be requested through prior authorization.
  • Non-covered drug. A few drugs are excluded entirely, but the exclusion is bounded. A formulary may leave out a covered outpatient drug for a specific condition only if the drug has no significant, clinically meaningful therapeutic advantage over what is on the formulary, and only if there is a written explanation of the basis for the exclusion available to the public. The state plan must still permit coverage of an excluded drug through prior authorization. Some drugs cannot be excluded at all: smoking-cessation agents, barbiturates, and benzodiazepines are named in the statute.

Federal Medicaid law lets a state steer prescribing through a Preferred Drug List and prior authorization, but under Section 1927(d) of the Social Security Act only on the 24-hour response and 72-hour emergency-supply conditions explained below. For drugs treating mental health and substance use conditions, the Mental Health Parity and Addiction Equity Act of 2008 (MHPAEA) adds a protection narrower than it is usually described. It does not require any plan to cover mental health or substance use benefits. Where a plan does cover them, prior authorization and other medical management techniques are nonquantitative treatment limitations, and the plan may apply one to those benefits only if the processes, strategies, evidentiary standards, or other factors behind it are comparable to, and applied no more stringently than, those used for medical and surgical benefits in the same classification. Prescription drugs are one of the six classifications tested separately.

MHPAEA does not cover Medicaid on its own terms. CMS's 2016 final rule applies the parity standards to Medicaid managed care organizations, Alternative Benefit Plans, and CHIP, so the protection reaches you through your CMO. Alternative Benefit Plan and CHIP enrollees are covered however they receive services. For any other Medicaid member, the protection follows MCO enrollment and does not reach state plan services delivered only through fee-for-service or primary care case management; CMS encourages, but does not require, states to extend it to primary care case management arrangements. Your parity rights run through that 2016 rule, not the employer and individual-market rules, so the May 15, 2025 federal decision not to enforce the new parts of the 2024 parity final rule concerns a different set of rules.

The 72-hour emergency supply

A state Medicaid program may require approval before a covered outpatient drug is dispensed only if its approval system provides a response within 24 hours of a prior authorization request and provides for dispensing at least a 72-hour supply of the drug in an emergency situation, as that emergency is defined by the Secretary of HHS. The 72-hour requirement does not reach the drug classes federal law lets a state exclude or restrict under section 1927(d)(2). The response need not be a final decision, and the 72-hour supply turns on an emergency situation, not on a prior authorization simply running slow.

That protection is a condition Congress placed on the state's prior authorization system, not a per-request entitlement. The statute does not say whether the same conditions bind prior authorization run by a CMO, though federal managed care rules send a plan's drug authorization decisions to the same 24-hour response provision rather than the 7-day clock. If you are in a CMO, ask the plan or your pharmacy what emergency supply its rules allow.

Federal rule caps a plan's standard service-authorization decision at 7 calendar days after it receives the request (for rating periods starting on or after January 1, 2026), with 72 hours for an expedited decision when standard timing could seriously jeopardize your life, health, or ability to attain, maintain, or regain maximum function, each extendable by up to 14 more days. But 42 CFR 438.210(d)(3) expressly carves covered outpatient drugs out of those timeframes and sends them to the notice rule at section 1927(d)(5)(A) of the Social Security Act instead. So do not hold your CMO to 7 days on a pharmacy prior authorization; ask the plan which timeframe it applies to drugs. If you are a dual eligible in an integrated Medicare-Medicaid plan, a different set of Part C timelines applies again.

If your pharmacy says a drug needs prior authorization:

1
Step 1

Get the PA request submitted

Ask the pharmacy to submit the prior authorization request, or call your prescriber to do it right away.

2
Step 2

Ask for the 72-hour emergency supply

Tell the pharmacy you need the medication now and ask about a 72-hour emergency supply. Federal law makes this a condition on the state's approval system, and it applies in an emergency situation; if you are in a CMO, ask what your plan's rules allow.

3
Step 3

Send the supporting documentation

Have your prescriber submit the diagnosis, the drugs already tried, and the clinical reason for this drug.

4
Step 4

Fill it or appeal

If approved, return to the pharmacy. If denied, appeal.

How to appeal a Georgia Medicaid drug denial

A prior authorization denial is not the end. Every denial comes with appeal rights, and the deadlines are specific.

When a CMO denies coverage, it must send a written Notice of Adverse Benefit Determination explaining the decision and your appeal rights. That notice carries a right worth using: on request and free of charge you can get reasonable access to and copies of every document, record, and piece of information relevant to the determination, including the medical-necessity criteria and the processes, strategies, and evidentiary standards the plan used to set coverage limits. Ask for them; they are what your prescriber rebuts. Where the plan is terminating, suspending, or reducing a service it already authorized, the notice must be mailed on the advance-notice timeline, which MACPAC renders as at least 10 days before the action. Federal rules allow exceptions, such as 5 days' notice where the agency has facts indicating probable fraud, so shorter notice is not automatically defective. From there:

1
Step 1

Appeal to your plan within 60 calendar days

Federal managed care rules give you 60 calendar days from the date on the denial notice to appeal to your CMO, orally or in writing, and the plan gets only one level of appeal. Where state law permits and you give written consent, your prescriber or an authorized representative can file it for you, though a provider cannot request continuation of benefits on your behalf. The 60 days is the appeal deadline only; a grievance can be filed at any time. A dual eligible in an integrated Medicare-Medicaid plan follows a different rule.

2
Step 2

The plan decides within set timeframes

Georgia sets the deadlines and federal rule caps them: no longer than 30 calendar days from the day the plan receives a standard appeal, and no longer than 72 hours for an expedited appeal (when standard timing could jeopardize your health). Either can be extended by up to 14 calendar days if you request it, or if the plan shows the state that more information is needed and the delay is in your interest. An extension you did not ask for is not free to the plan: it must try to reach you promptly by phone, give you written notice of the reason within 2 calendar days, and tell you that you may file a grievance if you disagree. A plan that misses these appeal-resolution notice and timing rules deems you to have exhausted its appeal, letting you go straight to a State Fair Hearing. Ask your prescriber to submit documentation supporting medical necessity.

3
Step 3

Ask for continued benefits, in writing, on a 10-day clock

In managed care, continuation is not automatic and it is not the same rule as an eligibility appeal. Under 42 CFR 438.420 the plan must keep the drug going only if all five conditions are met: you filed the plan appeal on time; the appeal is about the termination, suspension, or reduction of a service already authorized; the service was ordered by an authorized provider; the original authorization period has not expired; and you filed for continuation on or before the later of 10 calendar days after the plan sent the denial notice or the intended effective date. Say explicitly that you want benefits continued. Note the cost risk: if the final decision goes against you, the plan may recover the cost of what it furnished only because you asked for continuation, consistent with the federal recoupment rule that lets an agency recoup services furnished solely because benefits continued (42 CFR 431.230(b)).

4
Step 4

Request a State Fair Hearing if the plan upholds the denial, but watch the second, shorter clock

After you exhaust your CMO's one internal appeal, the state must give you no less than 90 and no more than 120 calendar days from the date of the plan's notice of resolution to request a State Fair Hearing. In Georgia, state agencies transmit Medicaid hearing requests to the Georgia Office of State Administrative Hearings (OSAH), the separate hearings tribunal. Each state sets the exact number within that band, so treat 90 days as your working deadline and confirm Georgia's current window with DCH or OSAH.

Continued benefits end if you do not request both the hearing and continuation within 10 calendar days of the plan sending its adverse resolution. Take the full 90 days to file and you keep the appeal but lose the coverage in the meantime. If the drug matters now, file inside 10 days.

5
Step 5

Get legal help

OSAH tells hearing participants with limited income to call the Georgia Legal Services Program at 1-800-498-9469.

The Preferred Drug List and prior authorization

Georgia's fee-for-service program keeps its own drug list, and each CMO manages its own drug formulary alongside it, so a CMO member should work from their plan's formulary rather than the fee-for-service list. Section 1927(d) of the Social Security Act is the statutory basis for a preferred drug list on which non-preferred drugs require prior authorization.

Medicaid drug cost sharing is nominal and capped by federal rule, though the number in the regulation is not the number in force. For members at or below 150 percent of the federal poverty level, 42 CFR 447.53(b) sets base amounts of $4 for a preferred drug and $8 for a non-preferred drug, and provides that those dollar maximums rise each year, beginning October 1, 2015, by medical inflation, so the ceiling in force today is higher than the printed figure. Don't rely on Medicaid.gov's own table for today's number: it still shows the FY 2013 amounts. Total premiums and cost sharing for the whole Medicaid household cannot exceed 5 percent of family income, and the agency must tell you when you reach that limit and let you ask for a reassessment if your circumstances change.

Being in an exempt group does not automatically mean free drugs: 42 CFR 447.53(d) lets the agency charge an otherwise exempt person up to the non-preferred maximum on a non-preferred drug. There is a way out: under 42 CFR 447.53(e), for a non-preferred drug in a class of therapeutically equivalent or similar drugs, if your prescriber determines the preferred drug for your condition would be less effective for you, would have adverse effects, or both, the agency must have a timely process that drops your cost sharing to the preferred-drug amount. Ask for that determination in writing. The exempt groups include children in the listed categories, pregnant women through the postpartum period (with limited exceptions), anyone whose institutional or home-and-community-based assistance is already reduced by income beyond a personal needs amount, people receiving hospice care, and Indians who received an item or service from an Indian health care provider. No provider may deny services because you cannot pay the cost sharing, unless the state lets providers require payment from members with family income above 100 percent of the federal poverty level who are not in an exempt group, but an unpaid copay is not forgiven, and you can still be held liable for it.

If you get care at an FQHC: 340B pharmacies

If you get care at a Federally Qualified Health Center (FQHC) or another safety-net provider in Georgia, your prescriptions may run through the 340B Drug Pricing Program, a federal program under which covered providers buy outpatient drugs at a discounted 340B price.

For Medicaid patients, one rule matters: federal law prohibits a "duplicate discount," so a manufacturer is not required to give both a 340B discounted price and a Medicaid rebate on the same drug, and covered entities must have mechanisms to prevent it. On the fee-for-service side, HRSA runs this through the Medicaid Exclusion File: each covered entity site tells HRSA whether it will use 340B drugs for its Medicaid fee-for-service patients (carve-in) or buy them another way (carve-out), state by state. That file does not apply to managed care. There the safeguard is contractual, under 42 CFR 438.3(s)(3), in states that do not collect managed care drug claims data from covered entities directly. If you get care at an FQHC, ask its pharmacy team whether your medications can be filled through its 340B pharmacy.

How the Georgia Medicaid PBM system works behind the scenes

You don't need this section to fill a prescription or appeal a denial.

The Medicaid Drug Rebate Program

Under the Medicaid Drug Rebate Program (Section 1927 of the Social Security Act), drug manufacturers must pay states a rebate on covered outpatient drugs dispensed to Medicaid members. Federal regulation sets the basic rebate: for a brand-name drug, the greater of the difference between the Average Manufacturer Price (AMP) and the manufacturer's best price, or 23.1 percent of AMP (17.1 percent for a clotting factor or a drug approved only for pediatric use); for a generic drug, 13 percent of AMP. An additional inflation-based rebate applies on top when a drug's AMP has risen faster than consumer prices (CPI-U) since its base date. In Georgia, a 2023 state study found that each plan negotiated rebates and preferred drug placement with manufacturers individually. Medicaid drug pricing also rests on federally defined benchmarks: actual acquisition cost, which is the state Medicaid agency's own determination of what pharmacies pay for a drug, and the National Average Drug Acquisition Cost (NADAC), published weekly on data.medicaid.gov as drug-acquisition-cost reference data.

Spread pricing, curtailed not eliminated

"Spread pricing" is the practice of a PBM billing a plan more for a drug than it pays the pharmacy and keeping the difference. Federal Medicaid managed care rules curtail it without flatly banning it: the medical loss ratio (MLR) rule requires prescription drug rebates to be deducted from a plan's medical claims and treats a PBM's retained spread and administrative fees as non-claims costs, so spread cannot inflate a plan's reported MLR. CMS applied that to PBMs in a May 15, 2019 informational bulletin on MLR requirements related to third-party vendors: a plan may not count its whole capitated payment to the PBM as incurred claims, which the PBM must instead calculate as what it actually pays the pharmacy, ingredient costs and dispensing fees, minus prescription drug rebates. The bulletin's one exception, for a subcontractor delivering covered services through its own employees, does not reach a PBM operating through a pharmacy network.

A related point often misstated: the "85 percent" MLR figure is a rate-setting standard CMS uses to judge whether a state's capitation rates are actuarially sound, not a mandate that every plan hit 85 percent or pay money back. A minimum-MLR floor with a payback is a state option.

Frequently Asked Questions

Who is my Georgia Medicaid plan's PBM?

Fee-for-service members' pharmacy claims run through OptumRx; CMO members (Amerigroup Community Care, CareSource, or Peach State Health Plan) get the benefit through their CMO or the PBM it subcontracts. Confirm yours by calling member services on your ID card.

What is prior authorization and how long does it take?

Prior authorization is the PBM's review and approval of a specific drug for you before it can be dispensed. It is required for non-preferred drugs, step-therapy drugs, and quantities above a limit. For fee-for-service members, federal law allows the requirement only if the state's system returns a response within 24 hours of the request, and a response is not necessarily a final approval or denial. For members in a CMO, the 7-day and 72-hour managed care caps do not govern a drug, because 42 CFR 438.210(d)(3) carves covered outpatient drugs out of them, so ask your plan what timeframe it applies.

What if my pharmacy refuses to fill my prescription?

Ask for the specific reason. If it is a prior authorization rejection from the PBM, follow the PA and emergency-supply steps above. If the pharmacy is out of stock, ask whether it can order the drug or transfer the prescription to another network pharmacy. For ongoing problems, file a grievance with your CMO; for pharmacy practice concerns, contact the Georgia State Board of Pharmacy.

Learn More

Your next step Get personalized help navigating Georgia Medicaid prescription denials and appeals at brevy.com.

The information on Brevy.com is for educational purposes only and is not a substitute for professional legal, financial, or medical advice. Rules vary by state and program and change frequently. Always verify with the relevant agency or a qualified professional. Brevy is not a law firm, financial advisor, or healthcare provider.

Still have questions?

Brevy answers from this guide and every other guide here, and can check what you qualify for.

BC

Brevy Care Team

Expert eldercare guidance from Brevy's team of healthcare professionals and researchers.